| Literature DB >> 31655423 |
E R Petersen1, C Ammitzbøll2, H B Søndergaard2, A B Oturai2, P S Sørensen2, A C Nilsson3, L Börnsen2, M von Essen2, F Sellebjerg2.
Abstract
The objectives were to study the expression of very late antigen (VLA)-4, melanoma cell adhesion molecule-1 (MCAM-1) and activated leukocyte cell adhesion molecule (ALCAM) on CD4+ T cells during natalizumab treatment and to investigate the association with disease activity. We find that subgroups of autoreactive T cells are retained in peripheral blood, in particular MOG-reactive CD4+ T cells expressing MCAM-1. The expression of MCAM-1 or ALCAM on CD4+ T cells was, however, not clearly associated with disease activity (clinical or MRI) during natalizumab treatment. We confirm upregulation of MCAM-1 on CD4+ T cells during natalizumab treatment while VLA-4 is downregulated.Entities:
Keywords: ALCAM; Adhesion molecules; Blood-brain barrier; MCAM-1; Multiple sclerosis; Natalizumab
Year: 2019 PMID： 31655423 DOI： 10.1016/j.jneuroim.2019.577085
Source DB: PubMed Journal: J Neuroimmunol ISSN： 0165-5728 Impact factor: 3.478